The prognostic value of N-terminal proB-type natriuretic peptide

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 4, 2005, Pages 194-201

  Costello Boerrigter, Lisa C ^a   Burnett Jr , John C ^a  

^a MAYO CLINIC   (United States)

Author keywords

B type natriuretic peptide; Biomarkers; Diagnosis; N terminal proB type natriuretic peptide; Prognosis

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CREATININE; INTERLEUKIN 6;

AMINO TERMINAL SEQUENCE; AMYLOIDOSIS; CLINICAL TRIAL; CONCENTRATION (PARAMETERS); CONFIDENCE INTERVAL; CONGESTIVE HEART FAILURE; CREATININE CLEARANCE; DIAGNOSTIC VALUE; DRUG MECHANISM; HEART MUSCLE ISCHEMIA; HUMAN; HYPERTENSION; LUNG EMBOLISM; MOLECULAR MECHANICS; MORTALITY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; REVIEW; ST SEGMENT ELEVATION; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; VALVULAR HEART DISEASE;

ACUTE DISEASE; BIOLOGICAL MARKERS; CORONARY DISEASE; HEART FAILURE, CONGESTIVE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; PROGNOSIS; RISK ASSESSMENT; SYNDROME; SYSTOLE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 20444457580     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0156     Document Type: Review

References (55)

1. de Bold AJ et al. (1996) Mechanical and neuroendocrine regulation of the endocrine heart. Cardiovasc Res 31: 7-18
2. Grantham JA et al. (1997) BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. Am J Physiol 272: R1077-R1083
3. Tsuruda T et al. (2002) Brain natriuretic Peptide is produced in cardiac fibroblasts and induces matrix metalloproteinases. Circ Res 91: 1127-1134
4. McCullough PA et al. (2002) B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study. Circulation 106: 416-422
5. Hobbs RE et al. (1996) Hemodynamic effects of a single intravenous injection of synthetic human brain natriuretic peptide in patients with heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 78: 896-901
6. Marcus LS et al. (1996) Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure. A double-blind, placebo-controlled, randomized crossover trial. Circulation 94: 3184-3189
7. Colucci WS et al. (2000) Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group. N Engl J Med 343:246-253
8. Goetze JP (2004) Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 50: 1503-1510
9. Pemberton CJ et al. (2000) Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension 36: 355-359
10. Hunt PJ at al. (1995) The amino-terminal portion of pro-brain natriuretic peptide (Pro-BNP) circulates in human plasma. Biochem Biophys Res Commun 214: 1175-1183
11. Pfister R et al. (2004) Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 6: 289-293
12. Hammerer-Lercher A et al. (2001) Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction. Clin Chim Acta 310: 193-197
13. Lainchbury JG et al. (2003) Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol 42: 728-735
14. Mueller T et al. (2004) Biochemical diagnosis of impaired left ventricular ejection fraction-comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP). Clin Chem Lab Med 42: 159-163
15. Hammerer- Lercher A et al. (2004) Natriuretic peptides as markers of mild forms of left ventricular dysfunction: effects of assays on diagnostic performance of markers. Clin Chem 50: 1174-1183
16. Mueller T et al. (2004) Head-to-head comparison of the diagnostic utility of BNP and NT-proBNP in symptomatic and asymptomatic structural heart disease. Clin Chim Acta 341: 41-48
17. Yeo KT et al. (2003) Multicenter evaluation of the Roche NT-proBNP assay and comparison to the Biosite Triage BNP assay. Clin Chim Acta 338: 107-115
18. Costello-Boerrigter LC et al. (2004) NT-proBNP is superior to BNP in the detection of left ventricular systolic dysfunction in the community. Circulation 110: II-368:A1755
19. Richards AM et al. (2001) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 37: 1781-1787
20. Richards M and Troughton RW (2004) NT-proBNP in heart failure: therapy decisions and monitoring. Eur J Heart Fail 6: 351-354
21. O'Brien RJ et al. (2003) Pre-discharge, but not admission, levels of NT-proBNP predict adverse prognosis following acute LVF. Eur J Heart Fail 5: 499-506
22. Gardner RS et al. (2003) N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 24: 1735-1743
23. Kirk V et al. (2004) N-terminal proBNP and mortality in hospitalised patients with heart failure and preserved vs. reduced systolic function: data from the prospective Copenhagen Hospital Heart Failure Study (CHHF). Eur J Heart Fail 6: 335-341
24. Groenning BA et al. (2004) Diagnostic and prognostic evaluation of left ventricular systolic heart failure by plasma N-terminal pro-brain natriuretic peptide concentrations in a large sample of the general population. Heart 90: 297-303
25. Packer M et al. (1996) The effect of carvedilol on morbidity and mortality in patients with chronic heart failure. US Carvedilol Heart Failure Study Group. N Engl J Med 334: 1349-1355
26. Merit-HF Study Group (1999) Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF). Lancet 353: 2001-2007
27. Packer M et al. (2001) Effect of carvedilol on survival in severe chronic heart failure. N Engl J Med 344: 1651-1658
28. Luchner A et al. (1998) Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. J Am Coll Cardiol 32: 1839-1844
29. Zugck C et al. (2002) Impact of beta-blocker treatment on the prognostic value of currently used risk predictors in congestive heart failure. J Am Coll Cardiol 39: 1615-1622
30. Hartmann F et al. (2004) Prognostic impact of plasma N-terminal pro-brain natriuretic peptide in severe chronic congestive heart failure: a substudy of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) trial. Circulation 110: 1780-1786
31. Richards AM et al. (1998) Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97: 1921-1929
32. Richards AM et al. (2003) B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 107: 2786-2792
33. Jernberg T et al. (2002) N-terminal pro brain natriuretic peptide on admission for early risk stratification of patients with chest pain and no ST-segment elevation. J Am Coll Cardiol 40: 437-445
34. Omland T et al. (2002) Prognostic value of N-terminal pro-atrial and pro-brain natriuretic peptide in patients with acute coronary syndromes. Am J Cardiol 89: 463-465
35. James SK et al. (2003) N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 108: 275-281
36. Jernberg T et al. (2003) N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease. J Am Coll Cardiol 42: 1909-1916
37. Bazzino O et al. (2004) Relative value of N-terminal probrain natriuretic peptide, TIMI risk score, ACC/AHA prognostic classification and other risk markers in patients with non-ST-elevation acute coronary syndromes. Eur Heart J 25: 859-866
38. Omland T et al. (2002) N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106: 2913-2918
39. Galvani M et al. (2004) N-terminal pro-brain natriuretic peptide on admission has prognostic value across the whole spectrum of acute coronary syndromes. Circulation 110: 128-134
40. de Lemos JA et al. (2001) The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med 345: 1014-1021
41. Galvani M et al. (2004) Natriuretic peptides for risk stratification of patients with acute coronary syndromes. Eur J Heart Fail 6: 327-333
42. Zuetenhorst JM et al. (2004) Role of natriuretic peptides in the diagnosis and treatment of patients with carcinoid heart disease. Br J Cancer 90: 2073-2079
43. Palladini G et al. (2003) Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 107: 2440-2445
44. Olsen MH et al. (2004) N-terminal pro-brain natriuretic peptide predicts cardiovascular events in patients with hypertension and left ventricular hypertrophy: a LIFE study. J Hypertens 22: 1597-1604
45. Kucher N et al. (2003) Low pro-brain natriuretic peptide levels predict benign clinical outcome in acute pulmonary embolism. Circulation 107: 1576-1578
46. Pruszczyk P et al. (2003) N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 22: 649-653
47. Gerber IL et al. (2003) Increased plasma natriuretic peptide levels reflect symptom onset in aortic stenosis. Circulation 107: 1884-1890
48. Weber M et al. (2004) Relation of N-terminal pro-B-type natriuretic peptide to severity of valvular aortic stenosis. Am J Cardiol 94: 740-745
49. Bergler-Klein J et al. (2004) Natriuretic peptides predict symptom-free survival and postoperative outcome in severe aortic stenosis. Circulation 109: 2302-2308
50. Sutton TM et al. (2003) Plasma natriuretic peptide levels increase with symptoms and severity of mitral regurgitation. J Am Coll Cardiol 41: 2280-2287
51. Herrmann Z et al. (2003) The influence of renal function on NT-proBNP levels in various disease groups. Clin Lab 49: 649-656
52. McCullough PA et al. (2003) B-type natriuretic peptides: a diagnostic breakthrough for clinicians. Rev Cardiovasc Med 4: 72-80
53. Apple FS et al. (2004) Multi-biomarker risk stratification of N-terminal pro-B-type natriuretic peptide, high-sensitivity C-reactive protein, and cardiac troponin T and I in end-stage renal disease for all-cause death. Clin Chem 50: 2279-2285
54. Wei Y et al. (2000) Corin, a transmembrane cardiac serine protease, acts as a pro-atrial natriuretic peptide-converting enzyme. Proc Natl Acad Sci USA 97: 8525-8529
55. Jiang W et al. (2005) Changes in production and metabolism of brain natriuretic peptide in rats with myocardial necrosis Eur J Pharmacol 507: 153-162